DK1809253T3 - Stabiliseret frysetørret formulering til cephalosporinderivater - Google Patents

Stabiliseret frysetørret formulering til cephalosporinderivater

Info

Publication number
DK1809253T3
DK1809253T3 DK05798682.0T DK05798682T DK1809253T3 DK 1809253 T3 DK1809253 T3 DK 1809253T3 DK 05798682 T DK05798682 T DK 05798682T DK 1809253 T3 DK1809253 T3 DK 1809253T3
Authority
DK
Denmark
Prior art keywords
dried formulation
cephalosporin derivatives
stabilized freeze
freeze
stabilized
Prior art date
Application number
DK05798682.0T
Other languages
English (en)
Inventor
Wilhelm Scigalla
Markus Heubes
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Application granted granted Critical
Publication of DK1809253T3 publication Critical patent/DK1809253T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05798682.0T 2004-11-10 2005-11-10 Stabiliseret frysetørret formulering til cephalosporinderivater DK1809253T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405690A EP1656930A1 (en) 2004-11-10 2004-11-10 Stabilized freeze-dried formulation for cephalosporin derivatives
PCT/CH2005/000665 WO2006050631A1 (en) 2004-11-10 2005-11-10 Stabilized freeze-dried formulation for cephalosporin derivatives

Publications (1)

Publication Number Publication Date
DK1809253T3 true DK1809253T3 (da) 2010-07-12

Family

ID=34932353

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05798682.0T DK1809253T3 (da) 2004-11-10 2005-11-10 Stabiliseret frysetørret formulering til cephalosporinderivater

Country Status (24)

Country Link
US (2) US20080032962A1 (da)
EP (3) EP1656930A1 (da)
JP (1) JP2008519775A (da)
KR (1) KR20070084150A (da)
CN (1) CN101056623B (da)
AR (1) AR052233A1 (da)
AT (1) ATE468844T1 (da)
AU (1) AU2005304252B2 (da)
BR (1) BRPI0517305A (da)
CA (1) CA2585296A1 (da)
CY (1) CY1110731T1 (da)
DE (1) DE602005021530D1 (da)
DK (1) DK1809253T3 (da)
ES (1) ES2342833T3 (da)
HR (1) HRP20100364T1 (da)
MX (1) MX2007005677A (da)
MY (1) MY142648A (da)
PL (1) PL1809253T3 (da)
PT (1) PT1809253E (da)
RS (1) RS51380B (da)
SI (1) SI1809253T1 (da)
TW (1) TW200630118A (da)
WO (1) WO2006050631A1 (da)
ZA (1) ZA200703760B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
BRPI0719393B8 (pt) 2006-12-07 2021-05-25 Daiichi Sankyo Co Ltd composição farmacêutica
US20100280064A1 (en) * 2006-12-07 2010-11-04 Tomoyuki Watanabe Pharmaceutical composition having improved storage stability
AU2009222020A1 (en) * 2008-03-04 2009-09-11 Elan Pharma International Limited Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US20130089638A1 (en) 2011-10-11 2013-04-11 Mead Johnson Nutrition Company Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes
CN102716075B (zh) * 2012-07-03 2013-08-21 哈药集团制药总厂 一种含有头孢唑肟钠的药物组合物
CN102727451B (zh) * 2012-07-03 2013-07-03 哈药集团制药总厂 一种含有头孢美唑钠的药物组合物
CN103271877A (zh) * 2012-12-18 2013-09-04 张宏民 一种头孢西丁钠注射剂及其制备方法
US9161990B2 (en) 2013-03-13 2015-10-20 Theravance Biopharma Antibiotics Ip, Llc Hydrochloride salts of a glycopeptide-cephalosporin antbiotic compond
CN110507619B (zh) * 2019-08-19 2021-12-03 湖北美林药业有限公司 注射用头孢哌酮钠及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690009B2 (ja) * 1986-07-10 1997-12-10 エーザイ 株式会社 セフアロスポリン注射剤
DE3801179A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
CA2026516C (en) * 1989-09-30 1998-02-17 Yasuo Ishibashi Injectable preparations containing cephalosporin medicament
JPH0459730A (ja) * 1990-06-26 1992-02-26 Dai Ichi Seiyaku Co Ltd セフェム系抗生物質含有凍結乾燥製剤
AU754732B2 (en) * 1998-06-15 2002-11-21 Basilea Pharmaceutica International Ag, Allschwil Derivatives of 3-(2-oxo-(1,3')bipyrrolidinyl-3-ylidenemethyl)-cephems
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
AU2003241675A1 (en) * 2002-06-21 2004-01-06 Shionogi And Co., Ltd. Medicinal cephem compound composition for injection

Also Published As

Publication number Publication date
EP1809253B1 (en) 2010-05-26
SI1809253T1 (sl) 2010-09-30
EP2210592A2 (en) 2010-07-28
US20100160278A1 (en) 2010-06-24
TW200630118A (en) 2006-09-01
RS51380B (en) 2011-02-28
ES2342833T3 (es) 2010-07-15
ZA200703760B (en) 2008-06-25
BRPI0517305A (pt) 2008-10-07
US20080032962A1 (en) 2008-02-07
AU2005304252B2 (en) 2009-07-16
MY142648A (en) 2010-12-15
JP2008519775A (ja) 2008-06-12
AU2005304252A1 (en) 2006-05-18
CA2585296A1 (en) 2006-05-18
CN101056623A (zh) 2007-10-17
MX2007005677A (es) 2007-07-20
WO2006050631A1 (en) 2006-05-18
CN101056623B (zh) 2011-04-06
EP1809253A1 (en) 2007-07-25
EP2210592A3 (en) 2011-12-14
PL1809253T3 (pl) 2010-10-29
PT1809253E (pt) 2010-09-03
HRP20100364T1 (hr) 2010-07-31
KR20070084150A (ko) 2007-08-24
CY1110731T1 (el) 2015-06-10
EP1656930A1 (en) 2006-05-17
AR052233A1 (es) 2007-03-07
DE602005021530D1 (de) 2010-07-08
ATE468844T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
DK1809253T3 (da) Stabiliseret frysetørret formulering til cephalosporinderivater
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
ITMI20050728A1 (it) Formulazione innovativa
NO20075628L (no) Farmasøytiske formuleringer
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
ATE415400T1 (de) Pyrazolopyridinderivate
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
ATE394399T1 (de) Tetrahydropyridoindolderivate
ATE540935T1 (de) Chinazolinderivate
ATE383361T1 (de) Pyrrazolopyrimidinderivate
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
RU2398586C3 (ru) Фармацевтическая композиция
DK1962808T3 (da) HCV prodrug-formulering
ATE412651T1 (de) Pyrrolopyridinderivate
ATE417830T1 (de) Sulfonylbenzimidazolderivate
BRPI0809346A2 (pt) Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
DK1868586T3 (da) Antiinflammatorisk formulering
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
DK1971588T3 (da) Tiglien-3-onderivater
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate